Difference between revisions of "Hürthle cell neoplasm"
Jump to navigation
Jump to search
| Line 27: | Line 27: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
!Size | !Size | ||
!Percentage malignant | !Percentage<br>malignant | ||
|- | |- | ||
| <=1 cm | | <=1 cm | ||
| Line 34: | Line 34: | ||
|- | |- | ||
| 1-4 cm | | 1-4 cm | ||
| 23% | | 23% | ||
|- | |- | ||
| >4 cm | | >4 cm | ||
Revision as of 22:11, 18 December 2015
Hürthle cell neoplasm is a rare tumour of the thyroid gland that can have a benign or malignant behaviour.
It may be referred to as oncocytic neoplasm.
Hürthle cell carcinoma and Hürthle cell adenoma redirect to here.
General
- Incidence: uncommon.
- This is a general category - includes:
- Hürthle cell adenoma.
- Hürthle cell carcinoma.
- Some advocate total thyroidectomy for all Hürthle cell neoplasms, as it is difficult to reliably differentiate adenomas and carcinomas.[1]
- It can be understood as a special type of follicular neoplasm (including follicular thyroid adenoma and follicular thyroid carcinoma).[2]
- High stage HCC has a poor prognosis.[3]
Adenoma versus carcinoma
Suggestive for carcinoma:[1]
- Male.
- >4 cm.
- Adenomas usu. <3 cm.
Definite for carcinoma:[1]
- Lymphovascular invasion.
- Capsular invasion.
Risk of malignancy by tumour size
Risk of malignancy by size:[4]
| Size | Percentage malignant |
|---|---|
| <=1 cm | 17% |
| 1-4 cm | 23% |
| >4 cm | 65% |
Gross
- Yellow.
- Encapsulated.
Microscopic
Features:[2]
- Oncocytes >= 75% of cells:
- Abundant granular, eosinophilic cytoplasm.
- Round regular nucleus +/- prominent nucleolus.
- +/-Degenerative changes.
Negatives:
- Lack nuclear features of papillary thyroid carcinoma.
- Lack features of medullary thyroid carcinoma.
DDx:[5]
- Papillary thyroid carcinoma oncocytic variant.
- Medullary thyroid carcinoma oncocytic variant.
- Others.
IHC
Features:
- TTF-1 +ve (2 of 6 cases in Bejarno et al.,[6] or 6 of 6 cases in Choi et al.[7]).
- Thyroglobulin (6 of 6 cases[6]).
- CK7 (4 of 6 cases[6]).
- HBME-1 +ve (focal in 4 of 6 cases[7]).
- HCK -ve (6 of 6 cases[7]).
- CK19 +ve (focal in 4 of 6 cases[7]).
See also
References
- ↑ 1.0 1.1 1.2 Wasvary, H.; Czako, P.; Poulik, J.; Lucas, R. (Aug 1998). "Unilateral lobectomy for Hurthle cell adenoma.". Am Surg 64 (8): 729-32; discussion 732-3. PMID 9697901.
- ↑ 2.0 2.1 Thompson, Lester D. R. (2006). Endocrine Pathology: A Volume in Foundations in Diagnostic Pathology Series (1st ed.). Churchill Livingstone. pp. 104. ISBN 978-0443066856.
- ↑ Chindris, AM.; Casler, JD.; Bernet, VJ.; Rivera, M.; Thomas, C.; Kachergus, JM.; Necela, BM.; Hay, ID. et al. (Jan 2015). "Clinical and molecular features of Hürthle cell carcinoma of the thyroid.". J Clin Endocrinol Metab 100 (1): 55-62. doi:10.1210/jc.2014-1634. PMID 25259908.
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedpmid9563543 - ↑ Montone KT, Baloch ZW, LiVolsi VA (August 2008). "The thyroid Hürthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review". Arch. Pathol. Lab. Med. 132 (8): 1241–50. PMID 18684023.
- ↑ 6.0 6.1 6.2 Bejarano, PA.; Nikiforov, YE.; Swenson, ES.; Biddinger, PW. (Sep 2000). "Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms.". Appl Immunohistochem Mol Morphol 8 (3): 189-94. PMID 10981870.
- ↑ 7.0 7.1 7.2 7.3 Choi, YL.; Kim, MK.; Suh, JW.; Han, J.; Kim, JH.; Yang, JH.; Nam, SJ. (Oct 2005). "Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas.". J Korean Med Sci 20 (5): 853-9. PMID 16224162.